Vernalis PLC Total Voting Rights (0134V)
31 October 2017 - 6:00PM
UK Regulatory
TIDMVER
RNS Number : 0134V
Vernalis PLC
31 October 2017
TOTAL VOTING RIGHTS
VERNALIS PLC (the "Company")
31 October 2017
Vernalis plc (LSE: VER) announces that the Company's total
issued share capital at the date of this announcement is
526,447,546 ordinary shares of 1p each, with one voting right per
share. There are no shares held in treasury.
The total number of voting rights in the Company is therefore
526,447,546.
The above figure of 526,447,546 shares may be used by
shareholders as a denominator for the calculations by which they
will determine if they are required to notify their interest in, or
change to their interest in, the Company.
- ends -
Enquiries:
+44 (0) 118 938
Vernalis plc: 0015
Ian Garland, Chief Executive
Officer
David Mackney, Chief Financial
Officer
Canaccord Genuity Limited
(Nominated Adviser and Joint +44 (0) 20 7523
Broker): 8000
Henry Fitzgerald-O'Connor
Emma Gabriel
+44 (0) 20 7408
Shore Capital (Joint Broker): 4090
Bidhi Bhoma
Toby Gibbs
+44 (0) 20 3727
FTI Consulting: 1000
Ben Atwell
Simon Conway
Stephanie Cuthbert
Stern Investor Relations: +1 212 362 1200
Stephanie Ascher
Jane Urheim
Notes to Editors
About Vernalis
Vernalis is a revenue generating, commercial stage
pharmaceutical company with significant expertise in drug
development. The Group has three approved products: Tuzistra(R) XR,
targeting the US prescription cough-cold market; Moxatag(R) , a
once-a-day formulation of the antibiotic, amoxicillin, indicated
for the treatment of tonsillitis and/or pharyngitis secondary to
Streptococcus pyogenes in adults and pediatric patients 12 years
and older; and frovatriptan for the acute treatment of migraine. It
has an exclusive licensing agreement to develop and commercialise
multiple novel products focussed on the US prescription cough-cold
market as well as eight programmes in its NCE development pipeline.
Vernalis has also significant expertise in fragment and structure
based drug discovery which it leverages to enter into
collaborations with larger pharmaceutical companies. The Company's
technologies, capabilities and products have been endorsed over the
last ten years by collaborations with leading pharmaceutical
companies, including Asahi Kasei Pharma, Biogen Idec, Endo, GSK,
Genentech, Lundbeck, Menarini, Novartis, Servier, and Tris.
For further information about Vernalis, please visit
www.vernalis.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
TVRURUNRBOAROAA
(END) Dow Jones Newswires
October 31, 2017 03:00 ET (07:00 GMT)
Vernalis (LSE:VER)
Historical Stock Chart
From Apr 2024 to May 2024
Vernalis (LSE:VER)
Historical Stock Chart
From May 2023 to May 2024